



RESULTS OF ANNUAL GENERAL MEETING

MELBOURNE (AUSTRALIA) 14 November 2024: In accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth), the attached information is provided in relation to the resolutions put to shareholders of Invion Limited (ASX: IVX) ("**Invion**") at its 2024 Annual General Meeting held earlier today.

This announcement was approved for release by the Company Secretary of Invion Limited.

Investor and Media enquiries:

Thian Chew (Chairman & CEO)

T: +61 3 9692 7222

E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)

M: +61 409 341 613

E: brendon.lau@inviongroup.com

About Invion

Invion is a life-science company that is leading the global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Hong Kong and the rest of Asia Pacific, excluding China, Macau, Taiwan and Japan, to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia and Oceania, excluding China, Hong Kong, Taiwan, Macau, the Middle East and Russia for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States, Canada and Hong Kong for infectious diseases. Research and clinical cancer trials are funded by the technology licensor, RMW Cho Group Limited. Invion is listed on the ASX (ASX: IVX).

About Photodynamic Therapy (PDT)

Invion is developing Photosoft™ technology as a novel next generation Photodynamic Therapy (PDT). PDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, PDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. PDT has also demonstrated broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant "superbugs".

Invin Limited
2024 Annual General Meeting
Thursday, 14 November 2024
Results of Meeting

The following information is provided in accordance with section 251AA(2) of Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution Details		Instructions given to validly appointed proxies (as at proxy close)				Number of votes cast on the poll (where applicable)			Resolution Results
Resolution	Resolution Type	For	Against	Proxy's Discretion	Abstain	For	Against	Abstain*	Carried / Not Carried
1. Adoption of Remuneration Report	Ordinary	519,590,630 96.48%	8,457,025 1.57%	10,489,025 1.95%	1,299,576 -	546,490,933 98.48%	8,457,025 1.52%	5,379,701 -	Carried
2. Election of Ms Melanie Leydin as a Director of the Company	Ordinary	167,874,557 97.95%	615,716 0.04%	34,459,807 2.01%	710,696 -	222,185,767 99.72%	615,716 0.28%	710,696 -	Carried
3. Re-election of Mr Alan Yamashita as a Director of the Company	Ordinary	167,737,845 97.90%	5,376,928 0.31%	30,679,114 1.79%	1,097,291 -	213,828,237 97.55%	5,376,928 2.45%	5,537,416 -	Carried
4. Ratification of prior issue of Lind Shares	Ordinary	159,381,441 94.21%	899,424 0.05%	97,083,841 5.74%	22,734,114 -	256,565,282 99.65%	899,424 0.35%	22,174,239 -	Carried
5. Appointment of Auditor	Ordinary	170,014,247 99.16%	747,509 0.04%	13,641,806 0.80%	- -	183,756,053 99.59%	747,509 0.41%	4,440,125 -	Carried
6a. Approval of Issue of Options to Directors - Issue of Options to Mr Thian Chew	Ordinary	112,478,640 96.45%	30,881,516 2.65%	10,489,025 0.90%	3,157,122 -	123,067,665 79.94%	30,881,516 20.06%	7,597,247 -	Carried
6b. Approval of Issue of Options to Directors - Issue of Options to Mr Alan Yamashita	Ordinary	165,916,904 97.56%	30,852,414 1.81%	10,687,034 0.63%	2,959,113 -	176,703,938 85.14%	30,851,414 14.86%	7,399,238 -	Carried
6c. Approval of Issue of Options to Directors - Issue of Options to Mr Alistair Bennallack	Ordinary	165,007,821 97.55%	30,881,516 1.83%	10,564,951 0.62%	3,257,122 -	175,672,772 85.05%	30,881,516 14.95%	7,697,247 -	Carried
7. 100:1 Consolidation of Capital of the Company	Ordinary	166,866,473 97.47%	32,877,143 1.92%	10,489,025 0.61%	2,500,888 -	177,355,498 84.36%	32,877,143 15.64%	6,941,013 -	Carried
8. Approval of 10% Placement Facility	Special	169,371,401 98.97%	7,245,351 0.42%	10,489,025 0.61%	3,083,397 -	179,960,426 96.13%	7,245,351 3.87%	175,584,964	Carried

*Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.